Baker Bros. Advisors LP Design Therapeutics, Inc. Transaction History
Baker Bros. Advisors LP
- $8.39 Billion
- Q1 2025
A detailed history of Baker Bros. Advisors LP transactions in Design Therapeutics, Inc. stock. As of the latest transaction made, Baker Bros. Advisors LP holds 1,743,725 shares of DSGN stock, worth $6.75 Million. This represents 0.08% of its overall portfolio holdings.
Number of Shares
1,743,725
Previous 1,743,725
-0.0%
Holding current value
$6.75 Million
Previous $10.8 Million
37.44%
% of portfolio
0.08%
Previous 0.12%
Shares
8 transactions
Others Institutions Holding DSGN
# of Institutions
101Shares Held
33.4MCall Options Held
4KPut Options Held
3.1K-
Sr One Capital Management, LP6.53MShares$25.3 Million11.4% of portfolio
-
Logos Global Management LP San Francisco, CA4.22MShares$16.3 Million3.17% of portfolio
-
Black Rock Inc. New York, NY2.3MShares$8.92 Million0.0% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA1.95MShares$7.56 Million0.47% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct1.82MShares$7.04 Million0.02% of portfolio
About Design Therapeutics, Inc.
- Ticker DSGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,807,900
- Market Cap $216M
- Description
- Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ syste...